PDCD1 and neuroendocrine neoplasm: The recent research about neuroendocrine neoplasms found a negative correlation between progression-free survival after anti-PD-1 immunotherapy and expression of the CD69 activation marker on naïve T and NK cells in pre-treatment peripheral blood samples (MacFarlane et al., 2021).